Additional file 1 of Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report

資料集

Description

Additional file 1: Supplementary Figure 1. Immunohistochemistry (IHC) of the PD-L1 control. (a) Positive control of PD-L1 staining (Dako 22C3, tonsil). (b) Positive control of PD-L1 staining (Dako 28–8, tonsil)
可用日期2020
發行者Figshare

引用此